Our Blog & Resources

Unlock a goldmine of cutting-edge knowledge and resources on our blog, where we delve into the forefront of precision medicine, offering expert perspectives, actionable insights, and game-changing discoveries to empower your journey in shaping the future of healthcare. 

  • Poster
  • Press Release
  • Scientific Application Note
  • Scientific Review
  • Testimonial
  • Video
  • Webinar
  • White paper
  • Article
  • Case of the Month
  • Lab Case
1 - 32 of 120 results

Advanced filters :

Advanced filters :
Scientific Application Note

Cancer Management: Breast Cancer

5 min reading

What is Breast Cancer? With an estimated 2.26 million new cancer cases and 685 000 deaths in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in 2020,...

Scientific Application Note

What’s on the horizon for immunotherapy?

There’s an old adage in medicine that no sick patient should die without a trial of steroids. We are, perhaps, moving towards a similar paradigm in oncology, where everyone with advanced cancer receives a trial...

Scientific Application Note

Lung Cancer : Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis

Abstract Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib–osimertinib treatment in the global, observational GioTag study.  Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and...

Scientific Application Note

The fluid landscape of liquid biopsy

Analysis of circulating tumour dna (ctDNA), the so-called liquid biopsy, is fast, non-invasive and easy to arrange. So where is this technology best deployed? At diagnosis, liquid biopsy is limited by a lack of sensitivity....

Scientific Application Note

Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002)

Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P),...

Scientific Application Note

Biliary Tract Cancer Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

Oliver Klein, MD1,2; Damien Kee, MD1,3; Adnan Nagrial, MD4; etalBen Markman, MD5,6; Craig Underhill, MD7; Michael Michael, MD3; Louise Jackett, MD8; Caroline Lum, MD5; Andreas Behren, PhD2,9; Jodie Palmer, PhD2,9; Niall C. Tebbutt, MD1,10; Matteo S. Carlino, PhD4; Jonathan Cebon, PhD1,2,9 Author Affiliations JAMA Oncol. Published online July 30, 2020. doi:10.1001/jamaoncol.2020.2814 Key Points Question:  Is combination immunotherapy with nivolumab and ipilimumab associated with positive outcomes in patients with advanced biliary tract cancers?...

Scientific Application Note

BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Abstract PURPOSE: The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study, tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy...

Scientific Application Note

Oncology in the time of COVID

THE PARTIAL SUSPENSION OF ROUTINE CLINICAL SERVICES HAS IMPACTED THE DIAGNOSIS AND TREATMENT OF CANCER AROUND THE WORLD. In the UK, urgent referrals for suspected cancer are down by 60%1. Delays in diagnosis and surgery...

Scientific Application Note

COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy.

COVID-19 and CANCER With the spread of coronavirus disease 2019 (COVID-19), countries and states have instituted lockdowns. These decisions have been difficult and are sometimes described as benefiting the public health at the expense of...

Scientific Application Note

DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors Published online June 22, 2020. AbstractPURPOSE Preclinical studies demonstrated that ATR inhibition can...

Scientific Application Note

BLADDER CANCER: In a retrospective analysis, both ARID1A mutation and CXCL13 expression showed positive correlation with response to checkpoint inhibition, including overall survival. Combining the markers improved prediction.

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC Science Translational Medicine 17 Jun 2020: ABSTRACT Immune checkpoint therapy (ICT) can produce durable antitumor responses in...


Stay in the know

Get the latest resources, news and more.
This field is for validation purposes and should be left unchanged.